Skip to main content

Table 3 Adverse events experienced since study entry and the action taken

From: A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis

System

Adverse event

AZA

N = 15

MTX

N = 16

Outcome

CVS

Hypertension

2

4

Resolved on antihypertensives

 

Palpitations

2

0

Resolved- no action

 

Pedal edema

1

2

1 -required diuretics

Digestive

Diarrhoea

2

1

2- resolve on study withdrawal

1- resolve no action

 

Dyspepsia

1

7

Resolve on H2-R antagonist/PPI*

 

Excessive weight gain**

7

8

↓ prednisone if accompanied by other AEs

 

Gastric ulcer

0

1

Resolved on medical management

 

Increased appetite

1

0

No action

Endocrine

Diabetes requiring insulin

1

1

Controlled on insulin

 

NIDM new

3

1

Controlled on hypoglycemics & ↓ prednisone

 

Blurred vision-lens edema

0

1

Resolve on ↓ prednisone

 

Moon face

1

1

Improved on ↓ prednisone

 

Mouth ulcers

0

2

Resolve- no dose change

Nervous

Anxiety, insomnia, moody

5

0

Controlled on amitryptaline & ↓ prednisone

 

Cramps in legs

3

2

Controlled on K+ supplements

 

Dysesthesiae in feet

0

1

Improved on ↓ prednisone

 

Fatigue/asthenia

0

1

No action

 

Headache

0

1

Resolve -no action

 

Hearing loss

1

0

Resolve on study withdrawal

 

Tremors

0

2

Intermittent; no action

Respiratory

Pneumonia

1

0

Intravenous antibiotics

Skeletal

Arthralgia

1

2

Intermittent; no action

Skin

Acne/erythema/hirsutism

1

1

Resolve on prednisone reduction/withdrawal

 

Fungal infection

1

2

Resolve on topical antifungals & ↓ prednisone

 

Hidradenitis suppurativa

1

0

Oral antibiotics with incision drainage

  1. CVS refers to cardiovascular; AZA- azathioprine; MTX- methotrexate.
  2. * H2-R antagonist (histamine-2 receptor antagonist (cimetidine n = 5) or proton pump inhibitor (omeprazole n = 2))
  3. ** weight gain during the study of more than 10% of body weight at baseline visit.